Acceleration Consortium and SGC pair AI labs with open-science protein data

The Acceleration Consortium and the Structural Genomics Consortium have formalized a partnership pairing AC's self-driving labs, which use AI and robotics to automate chemical synthesis and testing, with SGC's open-science protein and ligand data. The stated goal is to feed SGC's Target 2035 initiative, which aims to produce a pharmacological tool for every human protein by 2035, by industrializing the medicinal-chemistry step that turns identified compounds into usable drug candidates. Cheryl Arrowsmith, chief scientist at SGC-Toronto, frames the deal as a response to a bottleneck: AI is generating validated chemical starting points faster than existing workflows can process. The announcement gives no timeline or metric for that speedup, only a figure of roughly $50 million in industry funding across the wider ecosystem it joins.